Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWong, Vanessa-
dc.contributor.authorde Boer, Richard-
dc.contributor.authorBaron-Hay, Sally-
dc.contributor.authorBlum, Robert-
dc.contributor.authorBoyle, Frances-
dc.contributor.authorChua, Susan-
dc.contributor.authorClarke, Kerrie-
dc.contributor.authorCuff, Katharine-
dc.contributor.authorGreen, Michael-
dc.contributor.authorLim, Elgene-
dc.contributor.authorMok, Kelly-
dc.contributor.authorNott, Louise-
dc.contributor.authorNottage, Michelle-
dc.contributor.authorTafreshi, Ali-
dc.contributor.authorTsoi, Daphne-
dc.contributor.authorUccellini, Anthony-
dc.contributor.authorHong, Wei-
dc.contributor.authorGibbs, Peter-
dc.contributor.authorLok, Sheau Wen-
dc.identifier.citationClinical Breast Cancer 2022; 22(8)en
dc.description.abstractInternational guidelines recommend combining a CDK4/6 inhibitor and endocrine therapy (ET) as first line treatment for hormone receptor (HR) positive, HER2 negative metastatic breast cancer (MBC). Results from MONALEESA-2 demonstrate superior progression free survival (PFS) and overall survival (OS) with ribociclib (CDK4/6 inhibitor) and ET compared to ET alone. Real world outcomes have yet to be reported. KARMA is a non-interventional registry of Australian patients receiving first-line treatment with ribociclib and aromatase inhibitor (AI), obtained via a Medicine Access Program (MAP) for HR+, HER2- MBC. Outcomes were compared with the ribociclib/letrozole cohort in MONALEESA-2. Data from 160 patients at 17 sites was analysed. Median follow-up is 36.5 months. Compared to MONALEESA-2, patients were numerically younger (54.3 vs. 62 years), with higher rates of bone-only metastases (31% vs. 21%). A total of 63 of 160 (39%) patients remain on treatment. A total of 56% of patients had at least 1 dose reduction, with neutropenia (68%) and abnormal liver enzymes (17%) the most common reasons. A total of 17 of 160 (11%) discontinued treatment due to toxicity, with no treatment related deaths. Median PFS was not reached (95% CI 29.9- NR), with PFS at 12 months and 18 months being 76% and 67% respectively versus 25.3 months, 73% and 63% in MONALEESA-2. The ribociclib and AI combination was well tolerated in this real-world setting. The KARMA registry cohort achieved a superior PFS (>36.5 months) to MONALEESA-2, potentially due to more favourable baseline disease characteristics. Less frequent assessment scheduling in this non trial setting may also contribute.en
dc.subjectBreast canceren
dc.subjectMedicine access programsen
dc.titleReal-World Outcomes of Ribociclib and Aromatase Inhibitor Use in First Line Hormone Receptor Positive, HER2-Negative Metastatic Breast Cancer.en
dc.typeJournal Articleen
dc.identifier.journaltitleClinical breast canceren
dc.identifier.affiliationThe Mater Hospital, North Sydney, NSW,Australiaen
dc.identifier.affiliationWollongong Private Hospital, Wollongong, NSW,Australiaen
dc.identifier.affiliationSt John of God Subiaco Hospital, Subiaco, WA,Australiaen
dc.identifier.affiliationPersonalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC,Australiaen
dc.identifier.affiliationNorthern Cancer Institute, St Leonards, NSW,Australiaen
dc.identifier.affiliationDepartment of Medical Oncology, Peter MacCallum Cancer Centre, Parkville, VIC,Australiaen
dc.identifier.affiliationSt Vincent's Private Hospital, Fitzroy, VIC,Australiaen
dc.identifier.affiliationOlivia Newton-John Cancer Wellness and Research Centreen
dc.identifier.affiliationDepartment of Medical Oncology, Western Health, Footscray, VIC,Australiaen
dc.identifier.affiliationDepartment of Medical Oncology, Bendigo Health, Bendigo, VIC,Australiaen
dc.identifier.affiliationDepartment of Medical Oncology, Eastern Health, Box Hill, VIC,Australiaen
dc.identifier.affiliationAlbury Wodonga Regional Cancer Centre, Albury Wodonga Health, East Albury, NSW,Australiaen
dc.identifier.affiliationDepartment of Medical Oncology, Princess Alexandra Hospital, Woolloongabba, QLD,Australiaen
dc.identifier.affiliationEpworth Freemasons, East Melbourne, VIC,Australiaen
dc.identifier.affiliationSt Vincent's Clinical School, University of New South Wales, NSW,Australiaen
dc.identifier.affiliationDepartment of Medical Oncology, Liverpool Hospital, Liverpool, NSW,Australiaen
dc.identifier.affiliationDepartment of Medical Oncology, Royal Hobart Hospital, Hobart, TAS,Australiaen
dc.identifier.affiliationDepartment of Medical Oncology, Royal Brisbane and Women's Hospital, Herston, QLD,Australiaen
dc.identifier.pubmedid36151018-, Vanessa
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.grantfulltextnone- Oncology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Oct 1, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.